{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T05:20:31Z","timestamp":1761110431948,"version":"build-2065373602"},"reference-count":53,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,3,26]],"date-time":"2020-03-26T00:00:00Z","timestamp":1585180800000},"content-version":"am","delay-in-days":419,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.lpm.2018.11.010","type":"journal-article","created":{"date-parts":[[2018,12,7]],"date-time":"2018-12-07T10:14:22Z","timestamp":1544177662000},"page":"154-164","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Les traitements anticoagulants oraux chez les personnes \u00e2g\u00e9es\u00a0: faut-il encore prescrire des antivitamines K\u00a0?"],"prefix":"10.1016","volume":"48","author":[{"given":"Carmelo","family":"Lafuente-Lafuente","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christel","family":"Oasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00ebl","family":"Belmin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2014","series-title":"Les anticoagulants en France en 2014\u00a0: \u00e9tat des lieux, synth\u00e8se et surveillance","author":"Agence National de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9 (ANSM)","key":"10.1016\/j.lpm.2018.11.010_bib0270"},{"issue":"1","key":"10.1016\/j.lpm.2018.11.010_bib0275","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/fcp.12091","article-title":"Pharmacology and mechanisms of action of new oral anticoagulants","volume":"29","author":"Salem","year":"2015","journal-title":"Fundam Clin Pharmacol"},{"issue":"16","key":"10.1016\/j.lpm.2018.11.010_bib0280","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018\u00a0European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.lpm.2018.11.010_bib0285","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.amjmed.2004.07.053","article-title":"Initiation of warfarin in elderly medical inpatients: a safe and accurate regimen","volume":"118","author":"Siguret","year":"2005","journal-title":"Am J Med"},{"key":"10.1016\/j.lpm.2018.11.010_bib0290","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/j.1532-5415.2009.02675.x","article-title":"Improving anticoagulation control in hospitalized elderly patients on warfarin","volume":"58","author":"Gouin-Thibault","year":"2010","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.lpm.2018.11.010_bib0295","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1161\/CIRCULATIONAHA.106.653048","article-title":"Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation","volume":"115","author":"Hylek","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2018.11.010_bib0300","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.pharmthera.2010.12.007","article-title":"The potential role of new oral anticoagulants in the prevention and treatment of thromboembolism","volume":"130","author":"Mavrakanas","year":"2011","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.lpm.2018.11.010_bib0305","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1160\/TH09-11-0758","article-title":"Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity","volume":"103","author":"van Ryn","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.lpm.2018.11.010_bib0310","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2165\/00003088-200847010-00005","article-title":"Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects","volume":"47","author":"Stangier","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.lpm.2018.11.010_bib0315","first-page":"455","article-title":"Effects of age and gender on the single-dose pharmacokinetics (PK) and pharmacodynamics (PD) of apixaban (abstract PP-MO-407)","volume":"7","author":"Frost","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.lpm.2018.11.010_bib0320","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1182\/blood.V108.11.905.905","article-title":"The effect of extreme age, and gender, on the pharmacology and tolerability of rivaroxaban: an oral, direct factor Xa inhibitor [abstract no 905]","volume":"108","author":"Kubitza","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2018.11.010_bib0325","doi-asserted-by":"crossref","first-page":"675","DOI":"10.2165\/11595320-000000000-00000","article-title":"Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention","volume":"50","author":"Mueck","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.lpm.2018.11.010_bib0330","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.thromres.2017.12.003","article-title":"Current evidence of oral anticoagulant reversal: a systematic review","volume":"162","author":"Tornkvist","year":"2018","journal-title":"Thromb Res"},{"key":"10.1016\/j.lpm.2018.11.010_bib0335","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"RE-LY Steering Committee and Investigators","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2018.11.010_bib0340","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"ROCKET AF Investigators","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2018.11.010_bib0345","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"ARISTOTLE Committees and Investigators","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2018.11.010_bib0350","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1161\/CIRCULATIONAHA.110.004747","article-title":"Risk of bleeding with 2\u00a0doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial","volume":"123","author":"Eikelboom","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2018.11.010_bib0355","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1016\/j.jacc.2016.09.944","article-title":"Causes of death in anticoagulated patients with atrial fibrillation","volume":"68","author":"Gomez-Outes","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.lpm.2018.11.010_bib0360","first-page":"CD008980","article-title":"Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation","volume":"3","author":"Bruins Slot","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.lpm.2018.11.010_bib0365","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1111\/jgs.12799","article-title":"New oral anticoagulants in elderly adults: evidence from a meta-analysis of randomized trials","volume":"62","author":"Sardar","year":"2014","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.lpm.2018.11.010_bib0370","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1161\/CIRCULATIONAHA.114.013267","article-title":"Efficacy and harms of direct oral anticoagulants in the elderly for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism: systematic review and meta-analysis","volume":"132","author":"Sharma","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2018.11.010_bib0375","unstructured":"Haute Autorit\u00e9 de Sant\u00e9 (HAS). Fiches de bon usage du m\u00e9dicament\u00a0: les anticoagulants oraux. Accessible (septembre 2018) sur\u00a0: https:\/\/www.has-sante.fr\/portail\/jcms\/c_2851086\/fr\/les-anticoagulants-oraux."},{"key":"10.1016\/j.lpm.2018.11.010_bib0380","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016\u00a0ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.lpm.2018.11.010_bib0385","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"RE-COVER Study Group","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2018.11.010_bib0390","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"Bauersachs","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2018.11.010_bib0395","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"B\u00fcller","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2018.11.010_bib0400","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2018.11.010_bib0405","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2018.11.010_bib0410","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2018.11.010_bib0415","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2018.11.010_bib0420","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2018.11.010_bib0425","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2018.11.010_bib0430","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1105819","article-title":"Apixaban with antiplatelet therapy after acute coronary syndrome","volume":"365","author":"Alexander","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2018.11.010_bib0435","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","article-title":"Dabigatran versus warfarin in patients with mechanical heart valves","volume":"369","author":"Eikelboom JW1","year":"2013","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.lpm.2018.11.010_bib0440","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1161\/STROKEAHA.117.017549","article-title":"Real-world setting comparison of nonvitamin-K antagonist oral anticoagulants versus vitamin-K antagonists for stroke prevention in atrial fibrillation: a systematic review and meta-analysis","volume":"48","author":"Ntaios","year":"2017","journal-title":"Stroke"},{"key":"10.1016\/j.lpm.2018.11.010_bib0445","article-title":"Oral anticoagulation in very elderly patients with atrial fibrillation \u2013 a nationwide cohort study","author":"Chao","year":"2018","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.lpm.2018.11.010_bib0450","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/jth.13985","article-title":"Variation of renal function over time is associated with major bleeding in patients treated with direct oral anticoagulants for atrial fibrillation","volume":"16","author":"Becattini","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.lpm.2018.11.010_bib0455","first-page":"CD011373","article-title":"Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease","volume":"11","author":"Kimachi","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.lpm.2018.11.010_bib0460","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1016\/j.jacc.2016.02.082","article-title":"Nonvitamin K anticoagulant agents in patients with advanced chronic kidney disease or on dialysis with AF","volume":"67","author":"Chan","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.lpm.2018.11.010_bib0465","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1046\/j.1365-2141.2003.04110.x","article-title":"Oral anticoagulants in the elderly","volume":"120","author":"Froom","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.lpm.2018.11.010_bib0470","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.amjmed.2006.07.045","article-title":"The safety of warfarin therapy in the nursing home setting","volume":"120","author":"Gurwitz","year":"2007","journal-title":"Am J Med"},{"key":"10.1016\/j.lpm.2018.11.010_bib0475","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jacc.2013.07.104","article-title":"The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial","volume":"63","author":"Reilly","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.lpm.2018.11.010_bib0480","doi-asserted-by":"crossref","first-page":"g4670","DOI":"10.1136\/bmj.g4670","article-title":"Dabigatran: how the drug company withheld important analyses","volume":"349","author":"Cohen","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.lpm.2018.11.010_bib0485","doi-asserted-by":"crossref","first-page":"h1857","DOI":"10.1136\/bmj.h1857","article-title":"Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study","volume":"350","author":"Abraham","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.lpm.2018.11.010_bib0490","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.jacc.2012.06.019","article-title":"Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS study","volume":"60","author":"Apostolakis","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.lpm.2018.11.010_bib0495","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1111\/jth.13361","article-title":"Low performance of bleeding risk models in the very elderly with atrial fibrillation using vitamin K antagonists","volume":"14","author":"Jaspers Focks","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"20","key":"10.1016\/j.lpm.2018.11.010_bib0500","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1093\/eurheartj\/ehw054","article-title":"The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation","volume":"37","author":"Hijazi","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.lpm.2018.11.010_bib0505","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/j.1538-7836.2012.04635.x","article-title":"Bleeding risk in randomized controlled trials comparing warfarin and aspirin: a systematic review and meta-analysis","volume":"10","author":"Warkentin","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.lpm.2018.11.010_bib0510","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1111\/jth.13697","article-title":"Bleeding risk of antiplatelet drugs compared with oral anticoagulants in older patients with atrial fibrillation: a systematic review and meta-analysis","volume":"15","author":"Melkonian","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"9","key":"10.1016\/j.lpm.2018.11.010_bib0515","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"Connolly","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2018.11.010_bib0520","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s40266-017-0477-3","article-title":"Underuse of oral anticoagulants and inappropriate prescription of antiplatelet therapy in older inpatients with atrial fibrillation","volume":"34","author":"Averlant","year":"2017","journal-title":"Drugs Aging"},{"key":"10.1016\/j.lpm.2018.11.010_bib0525","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1001\/archinte.164.18.2044","article-title":"Safety of anticoagulation therapy in well informed older patients","volume":"164","author":"Kagansky","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.lpm.2018.11.010_bib0265","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1161\/CIRCULATIONAHA.110.007864","article-title":"Bleeding risk in very old patients on vitamin K antagonist treatment","volume":"124","author":"Poli","year":"2011","journal-title":"Circulation"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498218304561?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498218304561?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:04:28Z","timestamp":1760105068000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498218304561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S0755498218304561"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2018.11.010","relation":{},"ISSN":["0755-4982"],"issn-type":[{"type":"print","value":"0755-4982"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Les traitements anticoagulants oraux chez les personnes \u00e2g\u00e9es\u00a0: faut-il encore prescrire des antivitamines K\u00a0?","name":"articletitle","label":"Article Title"},{"value":"La Presse M\u00e9dicale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2018.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}